WuXi Biologics (Cayman) (MEX:2269N) FFO


MEX:2269N WuXi Biologics (Cayman) Inc MEX:2269N
99 GF Score
Price MXN62.53
GF Value MXN72.14
! 3 Warning Signs
View Full Analysis

What is WuXi Biologics (Cayman) FFO?

FFO (Funds from operations) only applies to REITs.

MEX:2269N
99GF Score
WuXi Biologics (Cayman) Inc MEX:2269N
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is WuXi Biologics (Cayman) (MEX:2269N) Overvalued in 2026?

Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be undervalued. The current stock price of MXN62.53 is trading 13.3% below its estimated GF Value™ of MXN72.14.

Key valuation signals for MEX:2269N:

  • FFO:
  • GF Value™: MXN72.14 vs. price of MXN62.53 (13.3% below fair value)
  • GF Score™: 99/100 with 3 warning signs

No single metric tells the full story. See the MEX:2269N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

WuXi Biologics (Cayman) Business Description

Address No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
99GF Score

Get the complete analysis for MEX:2269N

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN62.53
Price
MXN72.14
GF Value